Pharma News

---

🔊 AstraZeneca's Imfinzi Wins FDA Approval for Limited-Stage Small Cell Lung Cancer
🔊Govorestat's FDA Approval Denied for Classic Galactosemia
🔊EMA Approves Ozempic Label Update to Include Kidney Disease Risk Reduction
🔊MHRA Approves Delgocitinib Cream for Treating Chronic Hand Eczema in Adults
🔊Saudi Arabia Secures Over $798M in Pharmaceutical Deals at CPHI Middle East
🔊FDA Accepts Ascendis Pharma’s TransCon™ hGH sBLA for Adult Growth Hormone Deficiency
🔊Chimerix Plans NDA for Dordaviprone Targeting Aggressive Glioma
🔊Chiesi and Protalix's Dose Variation for Fabry Disease Receives EMA Validation
🔊Base Therapeutics Gains FDA IND Approval for Base-Edited NK Cell Therapy with GenScript’s Platform
🔊Tobevibart and Elebsiran Gain FDA Breakthrough Therapy Designation for Chronic Hepatitis D Virus
🔊NeuroSense Gains Positive FDA Feedback on Phase 3 Study Design for PrimeC in ALS
🔊Sanofi Gains FDA Fast Track for Dual Vaccine Protecting Seniors from Flu and COVID-19
🔊AbbVie Reports Positive Phase 3 TEMPO-2 Results for Tavapadon in Parkinson's Disease
🔊Siga's Tpoxx Falls Short in Latest Mpox Treatment Study
🔊EMA Approves ATMP Classification for NEOGAP Therapeutics' Cancer Cell Therapy pTTL

🔊 Biocon Biologics' Yesintek Receives Green Light From FDA
🔊 Gland Pharma Receives FDA Approval for Latanoprost Ophthalmic Solution
🔊 MHRA Approves LEO Pharma’s Anzupgo Cream for Chronic Hand Eczema (CHE)
🔊 Stallergenes Greer’s Palforzia Receives Positive CHMP Opinion for Treating Toddlers with Peanut Allergy
🔊 Faron Pharma’s Bexmarilimab Receives UK Innovation Passport for Blood Cancer
🔊 MHRA Grants Innovation Passport Designation to ILiAD's BPZE1 Pertussis Vaccine
🔊 Roche Expands Portfolio with $1.5B Acquisition of San Diego Biotech
🔊 PTC Secures $1B Deal With Novartis for Huntington’s Disease Drug
🔊 GSK Enters $1B Deal for Exclusive Option on DualityBio’s ADC
🔊 Intas Acquires Udenyca from Coherus in $558M Deal
🔊 Mitsubishi Tanabe Signs $480M Biobucks Deal With Dewpoint for ALS Research
🔊 Amarna Partners with NorthX Biologics to Propel Nimvec™ AM510 Development
🔊 Merus’ Bizengri Secures FDA Accelerated Approval for NRG1+ Cancers
🔊 Mesoblast’s Revascor® Earns FDA RMAT Designation for Pediatric Congenital Heart Disease
🔊 Pif’s 101-PGC-005 Receives FDA Rare Pediatric Disease Status for Systemic Juvenile Idiopathic Arthritis
🔊 FDA Awards Fast Track Status to Rigel’s R289 for Lower-Risk Myelodysplastic Syndrome
🔊 FDA Grants Fast Track Designation to Lantern's Drug LP-184 for Triple Negative Breast Cancer
🔊 Corbus’ CRB-701 Receives FDA Fast Track Designation for Relapsed Metastatic Cervical Cancer
🔊 FDA Grants Orphan Drug Designation to Exegenesis Bio’s EXG110 for Fabry Disease Treatment
🔊 FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for Non-Small Cell Lung Cancer